These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32196722)

  • 1. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
    Morris LM; Lewis HA; Cornelius LA; Chen DY; Rosman IS
    J Cutan Pathol; 2020 Aug; 47(8):742-746. PubMed ID: 32196722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid.
    Shi CR; Otto TS; Thompson LL; Chang MS; Reynolds KL; Chen ST
    Eur J Cancer; 2021 Dec; 159():34-37. PubMed ID: 34731747
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
    Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
    Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X; Sui D; Wang D; Zhang L; Wang R
    Front Immunol; 2021; 12():731774. PubMed ID: 34594337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of immune checkpoint inhibitor-induced bullous pemphigoid.
    Apalla Z; Lallas A; Delli F; Lazaridou E; Papalampou S; Apostolidou S; Gerochristou M; Rigopoulos D; Stratigos A; Nikolaou V
    J Am Acad Dermatol; 2021 Feb; 84(2):540-543. PubMed ID: 32428613
    [No Abstract]   [Full Text] [Related]  

  • 7. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
    J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
    Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
    Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
    Guan S; Zhang L; Zhang J; Song W; Zhong D
    Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
    Mazumder A; Darji K; Smith K; Guo M
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
    Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
    [No Abstract]   [Full Text] [Related]  

  • 15. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
    Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
    JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer.
    Lee H; Chung JH; Jo SJ
    Int J Dermatol; 2020 Jun; 59(6):685-686. PubMed ID: 31782147
    [No Abstract]   [Full Text] [Related]  

  • 18. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
    J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Use of Rituximab and Intravenous Gamma Globulin to Treat Checkpoint Inhibitor- Induced Severe Lichen Planus Pemphigoides.
    Brennan M; Baldissano M; King L; Gaspari AA
    Skinmed; 2020; 18(4):246-249. PubMed ID: 33050991
    [No Abstract]   [Full Text] [Related]  

  • 20. Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients.
    Yun JSW; Chan OB; Goh M; McCormack CJ
    Australas J Dermatol; 2023 Feb; 64(1):131-137. PubMed ID: 36514287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.